Al Garfall
@AlGarfall
Followers
682
Following
230
Media
0
Statuses
259
Oncologist @PennMedicine @PennCancer specializing in multiple myeloma and cellular immunotherapy.
Philadelphia, PA
Joined July 2014
RT @Myeloma_Doc: #Myeloma Paper of the Day: US Myeloma Immunotherapy Consortium real-world experience w/ teclistamab for relapsed/refractor….
0
8
0
RT @PratzKW: @AlGarfall @rajshekharucms @BloodCancerTalk The key to this is to make the clinical care overlap with the research as much as….
0
1
0
Generate videos in just a few seconds. Try Grok Imagine, free for a limited time.
373
148
2K
RT @bhemato: Fantastic US-German collaboration!Congrats to friends from US Immunotherapy Consortium and Max, David and @NicoGagelmann from….
0
6
0
RT @MyelomaTeacher: Yesterday Blenrep was approved in Canada - today Blenrep was approved in the EU. This myeloma patient and research adv….
gsk.com
Sixth regulatory approval for Blenrep combinations with applications under review in all major markets
0
5
0
Many thanks to co-senior author, Dr. Shambavi Richard, all the investigators and their teams throughout the consortium, and the consortium leadership, Drs. @SurbhiSidanaMD, Doris Hansen, and @DrKrinaPatel .
0
0
0
(6) Median PFS in ≥VGPR patients was >16 months. (7) Even among patients with poor-prognosis features, a substantial portion still achieved VGPR, and those achieving VGPR had quite good PFS approaching/exceeding 12 months depending on the subset.
1
0
1
(3) Prior CAR (mainly ide-cel) patients responded similarly to BCMA-naive population if prior CAR was >9 months before tec. (4) Prior belantamab was not associated with inferior response. (5) Add'l key prognostic variables were ALC <250, high disease burden, and high ferritin;.
1
0
2
We analyzed >500 patients, including substantial proportions who would have been ineligible for MajesTEC-1 and who had received prior anti-BCMA therapy. Key learnings:. (1) No unexpected toxicity in real-world usage. (2) Similar ORR in the subgroup eligible for Tec-1.
1
0
1
Please check out our recently published analysis of real-world outcomes with teclistamab from the US Myeloma Immunotherapy Consortium, led by our former @PennMedicine fellow and now Assistant Professor at Jefferson, @BeaRazzo.
aacrjournals.org
Abstract. Teclistamab is an anti-CD3xBCMA bispecific antibody approved for use in relapsed/refractory multiple myeloma (MM). We undertook a retrospective study of post-approval, real-world outcomes...
1
0
2
RT @oncodaily: I Have Immense Faith in Oncologists’ Abilities to De-Escalate Bela-Maf - Rahul Banerjee (@RahulBanerjeeMD). @AlGarfall @Josh….
0
3
0
RT @Transplant_Doc: Sequential BCMA CAR-T Cell Therapy (cilta-cel in patients relapsing after ide-cel) in RRMM. N=10, VGPR: 100%, MRD-ve: 6….
ashpublications.org
Key Points. Sequential treatment with commercially available BCMA-directed CAR-T therapy in refractory myeloma is safe and efficaciousDuration of response
0
14
0
RT @SagarLonialMD: In a trial like this, really important to see the pfs not just mrd. We learned from the forte study that while delaying….
0
5
0
Very nice study by @SusanBal9 & @End_myeloma demonstrating marked reduction in MRD burden after auto SCT in patients receiving quad induction for myeloma #mmsm
1
2
13
RT @HadidiSamer: A phase 2 randomized study of modakafusp alfa as a single agent in patients with relapsed/refractory multiple myeloma @Blo….
0
6
0
RT @hiragss: Hence, limited duration treatment needs to be evaluated for these drugs in #mmsm @AlGarfall is leading LimiTEC study which stu….
0
4
0
NIH scientists have a cancer breakthrough. Layoffs are delaying it.
washingtonpost.com
A big step forward in cancer therapy has been slowed by layoffs and new restrictions at the National Institutes of Health, where it was developed.
0
0
1
RT @TargetedOnc: Alfred L. Garfall, MD, (@AlGarfall) emphasizes the critical importance of the National Institutes of Health funding for bi….
targetedonc.com
Alfred L. Garfall, MD, emphasizes the critical importance of the National Institutes of Health funding for biomedical research.
0
1
0
The bone marrow NK cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy
ashpublications.org
Key PointsA reduced proportion of CD16+ bone marrow NK cells at diagnosis was associated with decreased daratumumab-mediated NK-cell degranulation.Reduced
0
1
7
0
5
0